What is cisplatin etoposide?
Etoposide and cisplatin chemotherapy (EP) is a combination chemotherapy treatment used to treat different types of cancer. It is best to read this information with our general information about chemotherapy and the type of cancer you have.
What type of chemo is etoposide?
Drug type: Etoposide is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as a “plant alkaloid” and “topoisomerase II inhibitor.” (For more detail, see “How this drug works” section below).
Why etoposide is called VP 16?
Etoposide was first synthesized in 1966 and U.S. Food and Drug Administration approval was granted in 1983. The nickname VP-16 likely comes from a compounding of the last name of one of the chemists who performed early work on the drug (von Wartburg) and podophyllotoxin.
What goes first cisplatin or etoposide?
Beginning on the first day of radiotherapy, patients receive cisplatin IV over 2 hours and etoposide IV over 1 hour on day 1 and oral etoposide once daily on days 2 and 3. Chemotherapy repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Do you lose your hair with etoposide?
This medicine often causes a temporary loss of hair. After treatment with etoposide has ended, normal hair growth should return.
Who invented etoposide?
Stähelin, M.D. (20 October 1925 – 5 July 2011) was a Swiss pharmacologist with an outstanding record in basic and applied cancer and immunology research. He discovered two important drugs: etoposide and ciclosporin.
Does etoposide cause hair loss?
Why is taxol given before cisplatin?
When cisplatin precedes paclitaxel, profound and prolonged neutropenia may occur. This can delay the patient from receiving chemotherapy as prescribed. When the sequence is reversed (ie, paclitaxel before cisplatin), this detrimental side effect is diminished without negating efficacy.
What are the long term effects of cisplatin?
Cisplatin (CDDP) is a frequently employed chemotherapeutic drug both in curative and palliative settings. When cancer patients are cured due to CDDP therapy, they unfortunately often experience severe long‐term side effects including irreversible hearing loss (ototoxicity) and permanent neuronal and renal damage.